文献速递临床试验与 GCP

非马沙坦对比培哚普利联合或不联合利尿剂治疗老年原发性高血压的研究方案

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-07-01

本研究为随机双盲阳性对照多中心3期试验,纳入70岁及以上原发性高血压患者,比较非马沙坦与培哚普利精氨酸盐的疗效与安全性。主要终点为治疗8周后坐位收缩压较基线的变化,每组计划样本量119例。研究旨在验证非马沙坦降压效果不劣于培哚普利。

要点

  • 非马沙坦为选择性AT1受体阻断剂,拟验证其降压效果不劣于培哚普利。
  • 主要终点为8周坐位收缩压较基线变化,每组样本量119例。
  • 若证实不劣于现有药物,非马沙坦可成为老年高血压治疗选择之一。

核心结论

  • 研究旨在确认非马沙坦在老年原发性高血压患者中降压效果不劣于培哚普利且安全性可接受。

研究设计与样本

  • 随机、双盲、阳性对照、双平行组、可选滴定、多中心3期研究。
  • 研究人群为70岁及以上原发性高血压患者。
  • 每组计划样本量119例,以检验主要终点的把握度。

关键数值与推荐

  • 主要终点为研究药物给药8周后坐位收缩压较基线的变化。
  • 次要终点包括坐位舒张压较基线变化及4、16、24周时坐位收缩压和舒张压较基线变化。

临床怎么用

  • 若非马沙坦不劣于培哚普利,可作为老年高血压患者的治疗选择之一。
  • 研究结果有助于指导医生在老年高血压患者中选择降压药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension is an important risk factor for cardiovascular disease, even in the elderly. Fimasartan is a new non-peptide angiotensin II receptor blocker with a selective type I receptor blocking effect. The objective of this study is to confirm the safety and the non-inferiority of the blood pressure-lowering effect of fimasartan compared with those of perindopril, which has been proven safe and effective in elderly patients with hypertension. METHODS: This is a randomized, double-blind, active-controlled, two-parallel group, optional-titration, multicenter, phase 3 study comparing the efficacy and safety of fimasartan and perindopril arginine. The study population consists of individuals 70 years old or older with essential hypertension. The primary outcome will be a change in sitting systolic blood pressure from baseline after the administration of the investigational product for 8 weeks. The secondary outcomes will be a change in sitting diastolic blood pressure from baseline and changes in sitting systolic blood pressure and diastolic blood pressure from baseline after the administration of the investigational product for 4, 16, and 24 weeks. The sample size will be 119 subjects for each group to confer enough power to test for the primary outcome. DISCUSSION: Research to confirm the efficacy and safety of a new medicine compared with those of previously proven anti-hypertensive drugs is beneficial to guide physicians in the selection of therapeutic agents. If it is confirmed that the new drug is not inferior to the existing drug, the drug will be considered as an option in the treatment of hypertension in elderly patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03246555 , registered on July 25, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kang MG, Kim KI, Ihm SH, et al. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31262348. doi:10.1186/s13063-019-3466-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。